

Oncology Clinical Trials
Penn Medicine Lancaster General Health, Ann B. Barshinger Cancer Institute

	Study Title – updated 9/21/2020
BREAST	
Metamorph- Penn	Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer
NRG-BR004	NRG BR004: A randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
CCTG MA-39	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
GASTRIC	
SPOTLIGHT: 8951-CL-0301 ASTELLAS	Phase III, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus MFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
LUNG	
NRG-LU005	Limited Stage Small Cell Lung Cancer(LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
NRG-LU002	Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
OVARIAN	
NRG-GY009	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin And CTEP-Supplied Atezolizumab(IND#134427) Versus Pegulated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer
HEMATOLOGY	
STOP-CA-Penn	Statins TO Prevent the Cardiotoxicity from Anthracyclines
OTHER	
EAY131-MATCH ECOG	Molecular Analysis for Therapy Choice (MATCH)
PROMPT- Penn	Prospective Registry of MultiPlex Testing
ASCO COVID Registry	ASCO Survey on COVID-19 Oncology (ASCO) Registry
I-COPE Penn	Association Between Immune Checkpoint Blockade and COVID-19 Severity in Cancer Patients: An Observational Cohort Study